Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina

International Journal of Molecular Medicine

Volumn 26, Issue 1, 2010, Pages 135-142

  Obrosova, Irina G ^a   Maksimchyk, Yury ^a   Pacher, Pal ^b   Agardh, Elisabet ^d   Smith, Maj Lis ^d   El Remessy, Azza B ^c   Agardh, Carl David ^d  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Aldose reductase; Apoptosis; Fidarestat; Nitrated proteins; Retinal ischemia reperfusion; Sorbitol dehydrogenase

Indexed keywords

ALDEHYDE REDUCTASE; FIDARESTAT; FRUCTOSE; IDITOL DEHYDROGENASE; SORBITOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL NUCLEUS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; NICK END LABELING; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; RETINA INJURY; RETINA ISCHEMIA; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 77954735649     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000445     Document Type: Article

References (82)

1. Hers HG: The mechanism of the formation of seminal fructose and fetal fructose. Biochim Biophys Acta 37: 127-138, 1960.
2. Sato S, Mori K, Wyman M and Kador PF: Dose-dependent prevention of sugar cataracts in galactose-fed dogs by the aldose reductase inhibitor M79175. Exp Eye Res 66: 217-222, 1998.
3. Sun W, Oates PJ, Coutcher JB, Gerhardinger C and Lorenzi M: A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 55: 2757-2762, 2006.
4. Drel VR, Pacher P, Ali TK, Shin J, Julius U, El-Remessy AB and Obrosova IG: Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis: Int J Mol Med 21: 667-676, 2008.
5. Neuenschwander H, Takahashi Y and Kador PF: Dose-dependent reduction of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by the aldose reductase inhibitor M79175. J Ocul Pharmacol Ther 13: 517-528, 1997. (Pubitemid 28008755)
6. Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN and Stevens MJ: Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 52: 864-871, 2003.
7. Nakamura J, Kato K, Hamada Y, Nakayama M, Chaya S, Nakashima E, Naruse K, Kasuya Y, Mizubayashi R, Miwa K, Yasuda Y, Kamiya H, Ienaga K, Sakakibara F, Koh N and Hotta N: A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 48: 2090-2095, 1999.
8. Kato N, Mizuno K, Makino M, Suzuki T and Yagihashi S: Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats. Diabetes Res Clin Pract 50: 77-85, 2000.
9. Keegan A, Jack AM, Cotter MA and Cameron NE: Effects of aldose reductase inhibition on responses of the corpus cavernosum and mesenteric vascular bed of diabetic rats. J Cardiovasc Pharmacol 35: 606-613, 2000.
10. Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA and Stevens MJ: An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. FASEB J 16: 123-125, 2002.
11. Price SA, Agthong S, Middlemas AB and Tomlinson DR: Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase. Diabetes 53: 1851-1856, 2004.
12. Schrijvers BF, De Vriese AS and Flyvbjerg A: From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25: 971-1010, 2004.
13. Drel VR, Pacher P, Stevens MJ and Obrosova IG: Aldose reductase inhibition counteracts nitrosative stress and poly (ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells. Free Radic Biol Med 40: 1454-1465, 2006.
14. Lee AY, Chung SK and Chung SS: Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc Natl Acad Sci USA 92: 2780-2784, 1995.
15. Yagihashi S, Yamagishi SI, Wada Ri R, Baba M, Hohman TC, Yabe-Nishimura C and Kokai Y: Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 124: 2448-2458, 2001. (Pubitemid 33134934)
16. Ho EC, Lam KS, Chen YS, Yip JC, Arvindakshan M, Yamagishi S, Yagihashi S, Oates PJ, Ellery CA, Chung SS and Chung SK: Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 55: 1946-1953, 2006.
17. Cheung AK, Fung MK, Lo AC, Lam TT, So KF, Chung SS and Chung SK: Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes 54: 3119-3125, 2005.
18. Srivastava S, Vladykovskaya E, Barski OA, Spite M, Kaiserova K, Petrash JM, Chung SS, Hunt G, Dawn B and Bhatnagar A: Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice. Circ Res 105: 793-802, 2009.
19. Tammali R, Reddy AB, Ramana KV, Petrash JM and Srivastava SK: Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation. Carcinogenesis 30: 799-807, 2009.
20. Reddy AB, Srivastava SK and Ramana KV: Anti-inflammatory effect of aldose reductase inhibition in murine polymicrobial sepsis. Cytokine 48: 170-176, 2009.
21. Yadav UC, Naura AS, Aguilera-Aguirre L, Ramana KV, Boldogh I, Sur S, Boulares HA and Srivastava SK: Aldose reductase inhibition suppresses the expression of Th2 cytokines and airway inflammation in ovalbumin-induced asthma in mice. J Immunol 183: 4723-4732, 2009.
22. Yadav UC, Srivastava SK and Ramana KV: Aldose reductase inhibition prevents endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci 48: 4634-4642, 2007.
23. Hwang YC, Kaneko M, Bakr S, Liao H, Lu Y, Lewis ER, Yan S, Ii S, Itakura M, Rui L, Skopicki H, Homma S, Schmidt AM, Oates PJ, Szabolcs M and Ramasamy R: Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J 18: 1192-1199, 2004. (Pubitemid 39006881)
24. Ananthakrishnan R, Kaneko M, Hwang YC, Quadri N, Gomez T, Li Q, Caspersen C and Ramasamy R: Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol 296: H333-H341, 2009.
25. Tang WH, Kravtsov GM, Sauert M, Tong XY, Hou XY, Wong TM, Chung SK and Man Chung SS: Polyol pathway impairs the function of SERCA and RyR in ischemic-reperfused rat hearts by increasing oxidative modifications of these proteins. J Mol Cell Cardiol (In press).
26. Cheung AK, Lo AC, So KF, Chung SS and Chung SK: Gene deletion and pharmacological inhibition of aldose reductase protect against retinal ischemic injury. Exp Eye Res 85: 608-616, 2007.
27. Agardh CD, Agardh E, Obrosova IG and Smith ML: The aldose reductase inhibitor fidarestat suppresses ischemia-reperfusion-induced inflammatory response in rat retina. Pharmacology 84: 257-263, 2009.
28. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, Rosenbaum PS, Cerami A, Brines M and Rosenbaum DM: Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 99: 10659-10664, 2002.
29. Russo R, Rotiroti D, Tassorelli C, Nucci C, Bagetta G, Bucci MG, Corasaniti MT and Morrone LA: Identification of novel pharmacological targets to minimize excitotoxic retinal damage. Int Rev Neurobiol 85: 407-423, 2009.
30. Hotta N, Koh N, Sakakibara F, Nakamura J, Hara T, Hamada Y, Fukasawa H, Kakuta H and Sakamoto N: Effect of an aldose reductase inhibitor on abnormalities of electroretinogram and vascular factors in diabetic rats. Eur J Pharmacol 326: 45-51, 1997. (Pubitemid 27205044)
31. Block F and Schwarz M: The b-wave of the electroretinogram as an index of retinal ischemia. Gen Pharmacol 30: 281-287, 1998. (Pubitemid 28046496)
32. Kim KY, Ju WK and Neufeld AH: Neuronal susceptibility to damage: comparison of the retinas of young, old and old/caloric restricted rats before and after transient ischemia. Neurobiol Aging 25: 491-500, 2004.
33. Drel VR, Xu W, Zhang J, Kador PF, Ali TK, Shin J, Julius U, Slusher B, El-Remessy AB and Obrosova IG: Poly(ADPribose) polymerase inhibition counteracts cataract formation and early retinal changes in streptozotocin-diabetic rats. Invest Ophthalmol Vis Sci 50: 1778-1790, 2009.
34. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG and Gardner TW: Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102: 783-791, 1998.
35. Wilson CA, Berkowitz BA, Funatsu H, Metrikin DC, Harrison DW, Lam MK and Sonkin PL: Blood-retinal barrier breakdown following experimental retinal ischemia and reperfusion. Exp Eye Res 61: 547-557, 1995.
36. Rota R, Chiavaroli C, Garay RP and Hannaert P: Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats. Eur J Pharmacol 495: 217-224, 2004.
37. Steigerwalt R, Belcaro G, Cesarone MR, Di Renzo A, Grossi MG, Ricci A, Dugall M, Cacchio M and Schönlau F: Pycnogenol improves microcirculation, retinal edema, and visual acuity in early diabetic retinopathy. J Ocul Pharmacol Ther 25: 537-540, 2009.
38. Kato N, Yashima S, Suzuki T, Nakayama Y and Jomori T: Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J Diabetes Complications 17: 374-379, 2003.
39. Zheng L, Gong B, Hatala DA and Kern TS: Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes. Invest Ophthalmol Vis Sci 48: 361-367, 2007.
40. Campochiaro PA: Retinal and choroidal neovascularization. J Cell Physiol 184: 301-310, 2000.
41. Frank RN: Diabetic retinopathy. N Engl J Med 350: 48-58, 2004.
42. Tsujikawa A, Kiryu J, Dong J, Yasukawa T, Suzuma I, Takagi H and Ogura Y: Quantitative analysis of diabetic macular edema after scatter laser photocoagulation with the scanning retinal thickness analyzer. Retina 19: 59-64, 1999. (Pubitemid 30387542)
43. Gustavsson C, Agardh CD, Hagert P and Agardh E: Inflammatory markers in nondiabetic and diabetic rat retinas exposed to ischemia followed by reperfusion. Retina 28: 645-652, 2008.
44. Obrosova IG and Stevens MJ: Effect of dietary taurine supplementation on GSH and NAD(P)-redox status, lipid peroxidation, and energy metabolism in diabetic precataractous lens. Invest Ophthalmol Vis Sci 40: 680-688, 1999.
45. Obrosova IG, Stevens MJ and Lang HJ: Diabetes-induced changes in retinal NAD-redox status: pharmacological modulation and implications for pathogenesis of diabetic retinopathy. Pharmacology 62: 172-180, 2001.
46. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB and Liou GI: Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 168: 235-244, 2006.
47. Iwata K, Matsuno K, Nishinaka T, Persson C and Yabe- Nishimura C: Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism. J Pharmacol Sci 102: 37-46, 2006.
48. Yagihashi S, Mizukami H, Ogasawara S, Yamagishi SI, Nukada H, Kato N, Hibi C, Chung S and Chung S: The role of the polyol pathway in acute kidney injury caused by hindlimb ischaemia in mice. J Pathol (In press).
49. Schmidt RE, Dorsey DA, Beaudet LN, Plurad SB, Parvin CA, Yarasheski KE, Smith SR, Lang HJ, Williamson JR and Ido Y: Inhibition of sorbitol dehydrogenase exacerbates autonomic neuropathy in rats with streptozotocin-induced diabetes. J Neuropathol Exp Neurol 60: 1153-1169, 2001.
50. Kador PF, Inoue J, Secchi EF, Lizak MJ, Rodriguez L, Mori K, Greentree W, Blessing K, Lackner PA and Sato S: Effect of sorbitol dehydrogenase inhibition on sugar cataract formation in galactose-fed and diabetic rats. Exp Eye Res 67: 203-208, 1998.
51. Obrosova IG, Fathallah L and Lang HJ: Interaction between osmotic and oxidative stress in diabetic precataractous lens: studies with a sorbitol dehydrogenase inhibitor. Biochem Pharmacol 58: 1945-1954, 1999.
52. Obrosova IG, Fathallah L, Lang HJ and Greene DA: Evaluation of a sorbitol dehydrogenase inhibitor on diabetic peripheral nerve metabolism: a prevention study. Diabetologia 42: 1187-1194, 1999.
53. Schmidt RE, Dorsey DA, Beaudet LN, Parvin CA, Yarasheski KE, Smith SR, Williamson JR, Peterson RG and Oates PJ: A potent sorbitol dehydrogenase inhibitor exacerbates sympathetic autonomic neuropathy in rats with streptozotocin-induced diabetes. Exp Neurol 192: 407-419, 2005.
54. Tilton RG, Chang K, Nyengaard JR, Van den Enden M, Ido Y and Williamson JR: Inhibition of sorbitol dehydrogenase. Effects on vascular and neural dysfunction in streptozocin-induced diabetic rats. Diabetes 44: 234-242, 1995.
55. Ido Y, Nyengaard JR, Chang K, Tilton RG, Kilo C, Mylari BL, Oates PJ and Williamson JR: Early neural and vascular dysfunctions in diabetic rats are largely sequelae of increased sorbitol oxidation. Antioxid Redox Signal 12: 39-51, 2010.
56. Cameron NE, Cotter MA, Basso M and Hohman TC: Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 40: 271-281, 1997.
57. Ng TF, Lee FK, Song ZT, Calcutt NA, Lee AY, Chung SS and Chung SK: Effects of sorbitol dehydrogenase deficiency on nerve conduction in experimental diabetic mice. Diabetes 47: 961-966, 1998.
58. Li Q, Hwang YC, Ananthakrishnan R, Oates PJ, Guberski D and Ramasamy R: Polyol pathway and modulation of ischemia-reperfusion injury in Type 2 diabetic BBZ rat hearts. Cardiovasc Diabetol 7: 33, 2008.
59. Obrosova IG: Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications. Antioxid Redox Signal 7: 1543-1552, 2005.
60. Obrosova IG and Fathallah L: Evaluation of an aldose reductase inhibitor on lens metabolism, ATPases and antioxidative defense in streptozotocin-diabetic rats: an intervention study. Diabetologia 43: 1048-1055, 2000.
61. Hall KE, Liu J, Sima AA and Wiley JW: Impaired inhibitory Gprotein function contributes to increased calcium currents in rats with diabetic neuropathy. J Neurophysiol 86: 760-770, 2001. (Pubitemid 32738565)
62. Lal S, Szwergold BS, Taylor AH, Randall WC, Kappler F, Wells-Knecht K, Baynes JW and Brown TR: Metabolism of fructose-3-phosphate in the diabetic rat lens. Arch Biochem Biophys 318: 191-199, 1995.
63. Phillips SA, Mirrlees D and Thornalley PJ: Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil. Biochem Pharmacol 46: 805-811, 1993.
64. Hasuike Y, Nakanishi T, Otaki Y, Nanami M, Tanimoto T, Taniguchi N and Takamitsu Y: Plasma 3-deoxyglucosone elevation in chronic renal failure is associated with increased aldose reductase in erythrocytes. Am J Kidney Dis 40: 464-471, 2002.
65. Nagaraj RH, Prabhakaram M, Ortwerth BJ and Monnier VM: Suppression of pentosidine formation in galactosemic rat lens by an inhibitor of aldose reductase. Diabetes 43: 580-586, 1994. (Pubitemid 24096300)
66. Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y, Nagai R, Horiuchi S and Hotta N: Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 23: 1539-1544, 2000.
67. Ramana KV, Friedrich B, Tammali R, West MB, Bhatnagar A and Srivastava SK: Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells. Diabetes 54: 818-829, 2005.
68. Uehara K, Yamagishi S, Otsuki S, Chin S and Yagihashi S: Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. Diabetes 53: 3239-3247, 2004.
69. Zatechka DS Jr, Kador PF, Garcia-Castiñeiras S and Lou MF: Diabetes can alter the signal transduction pathways in the lens of rats. Diabetes 52: 1014-1022, 2003.
70. Obrosova IG, Pacher P, Szabó C, Zsengeller Z, Hirooka H, Stevens MJ and Yorek MA: Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 54: 234-242, 2005.
71. Ramos KM, Jiang Y, Svensson CI and Calcutt NA: Pathogenesis of spinally mediated hyperalgesia in diabetes. Diabetes 56: 1569-1576, 2007.
72. Ramana KV, Friedrich B, Srivastava S, Bhatnagar A and Srivastava SK: Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes 53: 2910-2920, 2004.
73. Ji D, Li GY and Osborne NN: Nicotinamide attenuates retinal ischemia and light insults to neurones. Neurochem Int 52: 786-798, 2008.
74. Sakai Y, Tanaka T, Seki M, Okuyama S, Fukuchi T, Yamagata K, Takei N, Nawa H and Abe H: Cyclooxygenase-2 plays a critical role in retinal ganglion cell death after transient ischemia: realtime monitoring of RGC survival using Thy-1-EGFP transgenic mice. Neurosci Res 65: 319-325, 2009.
75. Berger S, Savitz SI, Nijhawan S, Singh M, David J, Rosenbaum PS and Rosenbaum DM: Deleterious role of TNF-alpha in retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 49: 3605-3610, 2008.
76. Hata N, Oshitari T, Yokoyama A, Mitamura Y and Yamamoto S: Increased expression of IRE1alpha and stress-related signal transduction proteins in ischemia-reperfusion injured retina. Clin Ophthalmol 2: 743-752, 2008.
77. Naruse K, Nakamura J, Hamada Y, Nakayama M, Chaya S, Komori T, Kato K, Kasuya Y, Miwa K and Hotta N: Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes. Exp Eye Res 71: 309-315, 2000.
78. Takamura Y, Tomomatsu T, Kubo E, Tsuzuki S and Akagi Y: Role of the polyol pathway in high glucose-induced apoptosis of retinal pericytes and proliferation of endothelial cells. Invest Ophthalmol Vis Sci 49: 3216-3223, 2008.
79. Pacher P, Beckman JS and Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424, 2007.
80. Zhang B, Rusciano D and Osborne NN: Orally administered epigallocatechin gallate attenuates retinal neuronal death in vivo and light-induced apoptosis in vitro. Brain Res 1198: 141-152, 2008.
81. El-Remessy AB, Bartoli M, Platt DH, Fulton D and Caldwell RB: Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration. J Cell Sci 118: 243-252, 2005.
82. El-Remessy AB, Abou-Mohamed G, Caldwell RW and Caldwell RB: High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 44: 3135-3143, 2003.